In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eastern Europe: The Local Advantage

Executive Summary

As the Eastern European and CIS markets expand, in some cases accelerated by EU enlargement, firms like Menarini--which in 1992 bought a strong presence in the area through its acquisition of Berlin-Chemie--are set to benefit from increasing in-licensing opportunities and growing sales. Local expertise is paramount in these markets: they may represent biggest growth opportunity in Europe, but most are still complex bureaucratically and politically, and protectionism remains rife in many states.

You may also be interested in...



Zentiva: Expanding in the CEE through M&A

The formation of Zentiva through the merger of Léciva and Slovakofarma-the leading pharmaceutical players in the Czech and Slovak markets respectively-propels the merged entity into the top ranks of the CEE pharmaceutical industry and gives the company a firm base upon which to expand internationally. Yet unlike the majority of its peers who are looking to the West to drive future growth, Zentiva is looking East. The plan: to tap into the rapidly growing and less crowded CEE markets and lead the consolidation of the industry across the region.

Merck Opens Up to Europe

Despite a strong trend among Big Pharma towards in-licensing over the last decade, Merck & Co. hasn't been particularly willing to embrace research ideas outside its own labs. But that's changing. Merck's new European in-licensing initiative proves that the Big Pharma recognizes, and hopes to access, the wealth of science and potential deals beyond US borders.

Zentiva: Expanding in the CEE through M&A

The formation of Zentiva through the merger of Léciva and Slovakofarma-the leading pharmaceutical players in the Czech and Slovak markets respectively-propels the merged entity into the top ranks of the CEE pharmaceutical industry and gives the company a firm base upon which to expand internationally. Yet unlike the majority of its peers who are looking to the West to drive future growth, Zentiva is looking East. The plan: to tap into the rapidly growing and less crowded CEE markets and lead the consolidation of the industry across the region.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV004823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel